David Sidransky - Net Worth and Insider Trading
David Sidransky Net Worth
The estimated net worth of David Sidransky is at least $287 dollars as of 2024-04-16. David Sidransky is the Director of Ayala Pharmaceuticals Inc and owns about 250 shares of Ayala Pharmaceuticals Inc (ADXS) stock worth over $155. David Sidransky is the Director of Orgenesis Inc and owns about 180 shares of Orgenesis Inc (ORGS) stock worth over $90. David Sidransky is also the Director of Advaxis Inc and owns about 67 shares of Advaxis Inc (ADXS) stock worth over $42. Details can be seen in David Sidransky's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that David Sidransky has not made any transactions after 2020-12-23 and currently still holds the listed stock(s).
Transaction Summary of David Sidransky
David Sidransky Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, David Sidransky owns 7 companies in total, including Ayala Pharmaceuticals Inc (ADXS) , Advaxis Inc (ADXS) , and Orgenesis Inc (ORGS) among others .
Click here to see the complete history of David Sidransky’s form 4 insider trades.
Insider Ownership Summary of David Sidransky
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ADXS | Ayala Pharmaceuticals Inc | 2020-12-23 | director |
| ADXS | Advaxis Inc | 2016-08-09 | director |
| ORGS | Orgenesis Inc | 2020-05-20 | director |
| CSBR | Champions Oncology Inc | 2007-01-05 | 10 percent owner |
| IMNPQ | Immune Pharmaceuticals Inc | 2015-01-08 | director |
| AKTX | Akari Therapeutics PLC | 2015-01-01 | director |
| CCTS | Cactus Acquisition Corp 1 Ltd | 2021-10-28 | director |
David Sidransky Latest Holdings Summary
David Sidransky currently owns a total of 3 stocks. Among these stocks, David Sidransky owns 250 shares of Ayala Pharmaceuticals Inc (ADXS) as of December 23, 2020, with a value of $155 and a weighting of 54.13%. David Sidransky owns 180 shares of Orgenesis Inc (ORGS) as of May 20, 2020, with a value of $90 and a weighting of 31.36%. David Sidransky also owns 67 shares of Advaxis Inc (ADXS) as of August 9, 2016, with a value of $42 and a weighting of 14.51%.
Latest Holdings of David Sidransky
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ADXS | Ayala Pharmaceuticals Inc | 2020-12-23 | 250 | 0.62 | 155 |
| ORGS | Orgenesis Inc | 2020-05-20 | 180 | 0.50 | 90 |
| ADXS | Advaxis Inc | 2016-08-09 | 67 | 0.62 | 42 |
Holding Weightings of David Sidransky
David Sidransky Form 4 Trading Tracker
According to the SEC Form 4 filings, David Sidransky has made a total of 1 transactions in Ayala Pharmaceuticals Inc (ADXS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Ayala Pharmaceuticals Inc is the acquisition of 250 shares on December 23, 2020, which cost David Sidransky around $3,700.
According to the SEC Form 4 filings, David Sidransky has made a total of 1 transactions in Orgenesis Inc (ORGS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Orgenesis Inc is the acquisition of 180 shares on May 20, 2020, which cost David Sidransky around $1,073.
According to the SEC Form 4 filings, David Sidransky has made a total of 0 transactions in Advaxis Inc (ADXS) over the past 5 years. The most-recent trade in Advaxis Inc is the sale of 19 shares on August 9, 2016, which brought David Sidransky around $342,348.
Insider Trading History of David Sidransky
- 1
David Sidransky Trading Performance
GuruFocus tracks the stock performance after each of David Sidransky's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David Sidransky is -2.87%. GuruFocus also compares David Sidransky's trading performance to market benchmark return within the same time period. The performance of stocks bought by David Sidransky within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how David Sidransky's insider trading performs compared to the benchmark.
Performance of David Sidransky
Average Relative Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | 4.7 | -2.87 | -18.48 | -26.49 | -63.4 | -53.81 |
| Relative Return to S&P 500(%) | 0.53 | -12.82 | -35.81 | -60.51 | -71.73 | -64.31 |
David Sidransky Ownership Network
Ownership Network List of David Sidransky
Ownership Network Relation of David Sidransky
David Sidransky Owned Company Details
What does Ayala Pharmaceuticals Inc do?
Who are the key executives at Ayala Pharmaceuticals Inc?
David Sidransky is the director of Ayala Pharmaceuticals Inc. Other key executives at Ayala Pharmaceuticals Inc include other: shareholder of 10% holder Yair Chaim Schindel , director & CEO Roni Mamluk , and Chief Medical Officer Gary B. Gordon .
Ayala Pharmaceuticals Inc (ADXS) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Ayala Pharmaceuticals Inc (ADXS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ayala Pharmaceuticals Inc (ADXS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Ayala Pharmaceuticals Inc (ADXS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ayala Pharmaceuticals Inc Insider Transactions
David Sidransky Mailing Address
Above is the net worth, insider trading, and ownership report for David Sidransky. You might contact David Sidransky via mailing address: Johns Hopkins University, 720 Rutland Avenue, Baltimore Md 21205.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
